LPAR5 Antibody

What is the structural organization of LPAR5 and how does it affect antibody selection?

LPAR5 (also known as GPR92 or GPR93) is a G-protein coupled receptor with seven transmembrane domains, an extracellular N-terminus, and an intracellular C-terminal tail . When selecting antibodies, researchers must consider epitope accessibility - antibodies targeting extracellular domains are ideal for live cell applications, while those targeting intracellular regions require cell permeabilization. Epitope-specific antibodies allow for domain-specific investigations of receptor function, with commercially available options targeting extracellular domains (residues 261-276 in humans), cytoplasmic domains, and internal regions .

How does LPAR5 differ from other lysophosphatidic acid receptors?

LPAR5 belongs to the non-Edg family of LPA receptors (which includes LPA4, LPA5, and LPA6), distinguishing it from the Edg family receptors (LPA1, LPA2, and LPA3) . LPAR5 has unique signaling properties - unlike other LPA receptors, it produces cAMP in a Gs-independent manner while coupling to Gq to mobilize Ca²⁺ . Furthermore, LPAR5 demonstrates preferential activation by alkyl-LPA compared to acyl-LPA, particularly relevant in platelet-rich environments where alkyl-LPA is abundant .

What are the primary signaling pathways downstream of LPAR5 activation?

LPAR5 activation triggers multiple signaling pathways:

• Ca²⁺ mobilization through Gq coupling

• cAMP production through Gs-independent mechanisms

• Inhibition of BCR signaling in B cells via a Gα12/13-Arhgef1 pathway, which interferes with intracellular calcium store release and likely affects inositol 1,4,5-trisphosphate receptor activity

This diversity of signaling mechanisms necessitates careful experimental design when investigating LPAR5 function using antibody-based approaches.

What are the recommended applications and dilutions for LPAR5 antibodies?

Based on validated antibody products, the following applications and dilutions are recommended:

Optimal dilutions should be determined for each specific experiment and antibody .

How can I validate the specificity of an LPAR5 antibody in my experimental system?

To validate LPAR5 antibody specificity:

• Perform blocking peptide experiments - compare antibody staining with and without pre-incubation with the immunizing peptide (e.g., Human LPAR5 extracellular blocking peptide)

• Include positive and negative control cell lines - use cells with confirmed LPAR5 expression (e.g., human MEG-01 cells) as positive controls

• Compare LPAR5 knockout/knockdown samples with wild-type samples

• Test the antibody against transfected cells overexpressing LPAR5 versus empty vector controls

• Verify molecular weight on Western blots compared to theoretical predictions

• Cross-validate findings using antibodies targeting different LPAR5 epitopes

What are the best fixation and antigen retrieval methods for immunohistochemical detection of LPAR5?

For optimal IHC detection of LPAR5:

• Fixation: Immersion fixation in paraformaldehyde works well for both cell lines and tissue samples

• Antigen retrieval: Heat-induced epitope retrieval using basic antigen retrieval reagents is recommended for paraffin-embedded sections

• Blocking: Use appropriate blocking solutions containing BSA to reduce non-specific binding

• Detection systems: Both fluorescent secondary antibodies (for IF) and HRP-based detection systems (for DAB visualization) are effective

• Counterstaining: DAPI for fluorescent applications or hematoxylin for brightfield microscopy

In human colon tissue, LPAR5 staining is primarily localized to the cytoplasm of Goblet cells .

Where is LPAR5 predominantly expressed, and how should this inform experimental design?

LPAR5 shows distinct tissue expression patterns that should inform experimental design:

• High expression in platelets, consistent with its role in platelet activation by alkyl-LPA

• Expression in spleen, heart, placenta, liver, and colon tissues

• Present in neural tissues including astrocytes, sensory neurons, and motor neurons in the spinal cord

• Found in B lymphocytes where it regulates BCR signaling

• Detected in megakaryocytic cell lines (MEG-01 and K562)

• Expressed in intestinal tissues, playing a role in intestinal homeostasis

When designing experiments, researchers should select appropriate positive control tissues/cells based on these expression patterns and consider using tissue-specific knockout models for validation.

How can I differentiate between LPAR5 and other LPA receptors when they are co-expressed?

To differentiate between co-expressed LPA receptors:

• Use receptor-specific antibodies targeting unique epitopes of LPAR5 (e.g., extracellular loop-specific antibodies)

• Employ selective antagonists such as H2L 5987411 and H2L 5765834 for functional studies

• Design siRNA knockdown experiments targeting LPAR5-specific sequences

• Use LPAR5 knockout models for comparative studies (Lpar5−/− vs. wild-type)

• Perform detailed co-localization studies with antibodies against multiple LPA receptors

• Analyze receptor-specific signaling pathways (e.g., LPAR5's unique Gs-independent cAMP production)

How can LPAR5 antibodies be used to investigate receptor-mediated signaling in immune cells?

LPAR5 antibodies enable several approaches for studying immune cell signaling:

• Detection of LPAR5 expression in B cells and correlation with BCR signaling capacity

• Visualization of LPAR5 localization during immune cell activation using immunofluorescence

• Monitoring changes in LPAR5 expression levels following antigenic stimulation using flow cytometry or Western blotting

• Combination with calcium imaging to assess LPAR5's impact on intracellular calcium mobilization during BCR signaling

• Identification of LPAR5-interacting proteins via co-immunoprecipitation

• Tracking receptor internalization following activation using antibodies against extracellular epitopes

Research has revealed that LPAR5 negatively regulates BCR signaling in B cells via inhibition of calcium release from intracellular stores, ultimately limiting antibody responses .

What approaches can be used to study LPAR5's role in platelet activation?

To investigate LPAR5's function in platelet activation:

• Use anti-LPAR5 antibodies to confirm expression in human megakaryocytic cell lines and platelets

• Combine with siRNA-mediated knockdown to correlate LPAR5 expression with LPA-induced platelet shape change and aggregation

• Monitor changes in LPAR5 localization during platelet activation using immunofluorescence

• Apply LPAR5 antagonists (H2L 5987411 and H2L 5765834) alongside antibody detection to link receptor expression with function

• Compare responses between human platelets (where LPAR5 mediates LPA effects) and mouse platelets (where it does not)

• Perform detailed signaling studies to determine the pathway from LPAR5 activation to platelet aggregation

Studies have demonstrated that siRNA-mediated knockdown of LPAR5 in human megakaryocytic cell lines abolishes LPA-induced platelet shape change and aggregation, confirming LPAR5's crucial role in this process .

How can LPAR5 antibodies be utilized in neuroscience research, particularly regarding neuropathic pain?

LPAR5 has emerged as a critical factor in neuropathic pain development:

• Use antibodies to map LPAR5 expression in sensory neurons and spinal cord tissues

• Compare LPAR5 expression between normal and neuropathic pain models

• Combine antibody detection with electrophysiological measurements to correlate receptor expression with neuronal activity

• Investigate LPAR5 co-localization with pain-associated ion channels and receptors

• Monitor changes in LPAR5 expression following treatment with analgesics

Studies using LPAR5 knockout mice have demonstrated that these animals do not develop neuropathic pain, suggesting a crucial role for this receptor in pain pathophysiology .

What methodological approaches can resolve contradictory findings regarding LPAR5 function in different experimental systems?

To address contradictory findings:

• Standardize antibody validation procedures across research groups

• Verify antibody specificity using multiple approaches (blocking peptides, knockout controls)

• Directly compare human vs. mouse systems (e.g., the differing role of LPAR5 in human vs. mouse platelets)

• Assess cell-type specific functions using conditional knockout models and corresponding antibody staining

• Consider post-translational modifications and splice variants of LPAR5 that may affect antibody recognition

• Document detailed experimental conditions that may influence receptor signaling outcomes

For example, while LPAR5 mediates LPA-induced platelet activation in humans, this is not the case in mouse platelets, highlighting the importance of species-specific validation .

How can LPAR5 antibodies be employed to investigate intestinal homeostasis and disease?

For intestinal system research:

• Use IHC with LPAR5 antibodies to map expression patterns in normal vs. diseased intestinal tissues

• Perform co-localization studies with cell-type specific markers to identify LPAR5-expressing intestinal cell populations

• Monitor changes in LPAR5 expression during intestinal inflammation or cancer progression

• Compare LPAR5 signaling mechanisms in intestinal epithelial cells vs. immune cells

• Investigate LPAR5's role in gut-brain axis communication by examining receptor expression in enteric neurons

LPAR5 has been identified as a key player in regulating normal intestinal homeostasis, making it a promising target for studying gastrointestinal pathologies .

How should researchers address non-specific binding or high background when using LPAR5 antibodies?

When encountering high background:

• Optimize antibody concentration - test a dilution series to find the optimal signal-to-noise ratio

• Improve blocking protocols - extend blocking time or use alternative blocking reagents

• Validate specificity - always include appropriate negative controls and blocking peptide controls

• For Western blots - try different membrane types, blocking buffers, and washing protocols

• For IHC/IF - optimize antigen retrieval methods and reduce primary/secondary antibody incubation times

• Consider using more specific detection systems with lower background (e.g., tyramide signal amplification)

• For flow cytometry - implement thorough blocking of Fc receptors and optimize gating strategies

What methodological considerations are important when using LPAR5 antibodies to quantify expression levels?

For accurate quantification:

• Establish standard curves using recombinant LPAR5 protein of known concentration

• Include internal loading controls when performing Western blot quantification

• Standardize protein extraction protocols to ensure consistent recovery of membrane proteins

• Use appropriate normalization strategies for qPCR validation of antibody findings

• When performing tissue analysis, account for heterogeneity by analyzing multiple fields/sections

• For flow cytometry, use antibody binding capacity (ABC) beads to convert fluorescence intensity to molecules of equivalent soluble fluorochrome

• Consider the impact of receptor internalization and trafficking on apparent expression levels

Human LPAR5 has a theoretical molecular weight of 41.3 kDa, which should be verified in Western blot applications .